1 / 22

A population-based surveillance study on the prevalence and treatment of hepatitis C in Eston ia

A population-based surveillance study on the prevalence and treatment of hepatitis C in Eston ia. Kairi Mansberg PhD student University of Tartu, Department of Internal Medicine. background.

fahim
Télécharger la présentation

A population-based surveillance study on the prevalence and treatment of hepatitis C in Eston ia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A population-based surveillance study on the prevalence and treatment of hepatitis C in Estonia Kairi Mansberg PhD student University of Tartu, Department of InternalMedicine

  2. background • hepatitis C infection is a significant public health problem and a leading cause of chronic liver disease in Estonia • Estonian Society of Gastroenterology • multi-center, open-label study • study cohort of consecutive patients with acute hepatitis C, chronic hepatitis C, C-related cirrhosis, C-related hepatocellular carcinomarepresents of the real-life situation

  3. aim • characterize the patients with hepatitis C • analyse a real-life hepatitis C cohort of patients • describe the risk factors of hepatitis C • analyse antiviral treatment in real-life situation

  4. material and methods (1) • patients consecutively referred as in-patients and out-patients were recruited in 7 divisions of 5 hospitals by 37 gastroenterologists / infectious disease doctors • patients were required to meet the criteria of acute hepatitis C, chronic hepatitis C, C-related cirrhosis or C-related hepatocellular carcinoma • patients were included during a one-year recruitment period, 01.02.09-31.01.10 and followed till 31.07.11 • informed consent was obtained from all patients • Ethics Review Committee on Human Research of the University of Tartu approval was obtained

  5. material and methods (2) web-based eCase Report Form is used for data registration data are entered into an eCRF by doctor in the course of the study, the study monitor make site visits to verify eCRFs against source documentation monitoring is conducted in each study center 4 times per year data were analysed using descriptive statistics program Stata 10,0

  6. results: 518 patients were included

  7. results: distribution by gender and age

  8. results: distribution of risk factors

  9. results: age and risk factors

  10. results: distribution of diagnosis

  11. results: distribution of diagnosis

  12. results: c-chirrosis34% of patsients visit a doctor at the stage of cirrhosis.

  13. results: distribution by genotypes

  14. HCV genotypes in Estonia

  15. results: age and genotypes G1 starts from the age of 40, but in younger age groups the increasing importance G3

  16. results: genotypes and risk factors

  17. results: gender, age and genotypes G1 is most prevalent among male pt aged 40-49 and female pt aged 50-59. G3 iscommon in younger age groups of men and women

  18. conclusions (1) • study cohort of consecutive 518 patients is representative of the real-life situation • prevailing genotype in Estonia is 1B, but our data indicate the increasing importance of genotype 3 • in many patients HCV liver disease is diagnosed too late – in HCV-related cirrhosis stage

  19. conclusions (2) • 265 patients started antiviral treatment during the study period, which makes up 79% of all Estonian patients in whom treatment was started during the same period

  20. Plans for the future • to analyse antiviral treatment results in real-life situation • RVR, pEVR, cEVR, SVR • relapsers, nonresponders • to analyse adverse events during antiviral treatment in real-life situation • potential cooperation with Department of Microbiology of University of Tartu

  21. Acknowledgements Estonian Society of Gastroenterology Roche Estonia OÜ Tartu University Hospital Riina Salupere, Karin Kull, Katrin Labotkin, Hele Remmel, Seren Kivi, Leana Sits, Tiina Prükk, Rita Pihlak, Svetlana Proškina, Külliki Ainsalu West Tallinn Central Hospital Külliki Suurmaa, Vadim Brjalin, Anu Mäelt, Marina Levitševa, Kristi Ott, Nele Rasmann,Tiiu Aug, Dagmar Mägi East Talinn Central Hospital Triin Remmel, Maie Aua, Asta Kolde, Ene Halling, Benno Margus, Toomas Kariis, Peeter Kõiva Pärnu Hospital Krista Jaago, Kadi Kenk, Urve Mardna East Viru Central Hospital Jelena Šmidt, Svetlana Semjonova

More Related